newsfilter
← Latest News
Business Wire·

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with